In the last trading session, 2.36 million shares of the Verve Therapeutics Inc (NASDAQ:VERV) were traded, and its beta was 1.98. Most recently the company’s share price was $3.26, and it changed around $0.21 or 6.89% from the last close, which brings the market valuation of the company to $289.49M. VERV currently trades at a discount to its 52-week high of $9.31, offering almost -185.58% off that amount. The share price’s 52-week low was $2.86, which indicates that the current value has risen by an impressive 12.27% since then. We note from Verve Therapeutics Inc’s average daily trading volume that its 10-day average is 2.52 million shares, with the 3-month average coming to 1.61 million.
Verve Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.40. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended VERV as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight.
Verve Therapeutics Inc (NASDAQ:VERV) trade information
Instantly VERV has showed a green trend with a performance of 6.89% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.63 on recent trading dayincreased the stock’s daily price by 10.19%. The company’s shares are currently down -42.20% year-to-date, but still down -9.94% over the last five days. On the other hand, Verve Therapeutics Inc (NASDAQ:VERV) is -46.99% down in the 30-day period. We can see from the shorts that 16.63 million shares have been sold at a short interest cover period of 13.1 day(s).
The consensus price target as assigned by Wall Street analysts is $14.5, which translates to bulls needing to increase their stock price by 77.52% from its current value. Analyst projections state that VERV is forecast to be at a low of $14 and a high of $15.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -42.43%. Verve Therapeutics Inc earnings are expected to increase by -13.49% in 2025, but the outlook is positive 5.30% per year for the next five years.
VERV Dividends
Verve Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-26.
Verve Therapeutics Inc (NASDAQ:VERV)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 5.04% of Verve Therapeutics Inc shares, and 90.24% of them are in the hands of institutional investors. The stock currently has a share float of 95.03%. Verve Therapeutics Inc stock is held by 252.0 institutions, with ALPHABET INC. being the largest institutional investor. By 2024-06-30, it held 14.6618% of the shares, which is about 12.35 million shares worth $60.26 million.
BLACKROCK INC., with 7.8598% or 6.62 million shares worth $32.31 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.13 shares worth $6.95 million, making up 2.40% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 1.83 shares worth around $5.95 million, which represents about 2.06% of the total shares outstanding.
